Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key study A-PPI-14 in-depth review
Stopping a PPI can cause rebound heartburn
Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
Overview
Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058
After stopping esomeprazole, 44% of healthy volunteers had acid symptoms vs 15% on placebo.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Rebound symptoms after PPI.
- How was the study done?
Double-blind RCT.
- How many people, animals or samples were studied?
120 healthy adults.
- What was actually found?
More acid symptoms after withdrawal.
- How large was the observed effect?
44% vs 15%.
- What do the results mean in everyday life?
Expect temporary symptoms when stopping.
- What are the study's limitations?
Short follow-up; mild symptoms.
- What does it say about Elawady's specific claim?
Supports rebound, not 'addiction'.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Lifelong dependence.
Scientific in-depth review
1. Full reference
- Authors
- Reimer C, Søndergaard B, Hilsted L, Bytzer P
- Journal
- Gastroenterology
- Year
- 2009
- Identifier
- PMID 19362552 DOI 10.1053/j.gastro.2009.03.058
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Does rebound acid hypersecretion after PPI withdrawal cause acid-related symptoms?
3. Study design and population
- Study design
- Randomised controlled trial – Randomised, double-blind, placebo-controlled trial in healthy volunteers
- Population
Healthy volunteers
- Country
Denmark
- Period
12 weeks per participant
- Sample size
120 randomised (59 analysed per arm)
- Inclusion and exclusion criteria
Healthy volunteers without acid-related symptoms
4. Methods and endpoints
- Exposure / intervention
Esomeprazole 40 mg/d for 8 weeks, then 4 weeks placebo
- Comparator
12 weeks placebo
- Endpoints
GSRS weekly; clinically relevant acid-related symptom = score >2 on heartburn, regurgitation or dyspepsia items
- Statistical methods
Comparison of proportions and scores
5. Actual results
- Results
≥1 relevant acid-related symptom in weeks 9–12: 44% (26/59) vs 15% (9/59), P<.001. Weekly proportions PPI vs placebo: week 10 22% vs 7%; week 11 22% vs 5%; week 12 21% vs 2%. GSRS acid scores slightly higher (e.g. week 12 1.3 vs 1.0).
- Absolute risks
Absolute difference 29 percentage points over weeks 9–12 (44% vs 15%; calculated).
- Authors' conclusion
PPI therapy for 8 weeks induces acid-related symptoms in healthy volunteers after withdrawal; supports clinical relevance of RAHS.
6. Strengths
- Randomised, double-blind, placebo-controlled
- Healthy volunteers isolate drug effect
7. Weaknesses
- Small
- Short follow-up after withdrawal (4 weeks)
- Symptom scores, mild changes
- Healthy volunteers, not patients
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Simplified judgement from abstract: randomised, blinded, placebo-controlled; low risk of bias likely.
9. Assessment of the statistical interpretation
Large relative and absolute difference; mean score differences small (mild symptoms).
10. Relevance to the specific claim
C-PPI-06 (support); C-PPI-07 (mechanism only).
11. Independent contrary findings
Lødrup 2013 (I-PPI-06): no symptomatic rebound shown in reflux patients (weak studies).
12. Transferability to Germany and Europe
High: biology and trial populations comparable to European adults.
13. Overall methodological judgement
Good RCT demonstrating transient rebound symptoms; does not show long-term dependence.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | partly correct but over-interpreted |
14. Open questions
Does rebound drive long-term use in patients?
15. Linked fact checks
- After stopping a PPI, rebound acid hypersecretion can cause new heartburn and reflux symptoms, even in people who had none before. – Studies supporting the claim
- PPIs create dependency: the drug 'manufactures the disease it claims to treat', so that a short course for a passing complaint turns into chronic dependence and one 'cannot stop'. – Studies with mixed or unclear results
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
120 healthy volunteers: 8 weeks esomeprazole induced new reflux symptoms in 44% after withdrawal versus 15% placebo – iatrogenic dependency; narrative: 'the drug manufactures the disease … you cannot stop'.
- A. What was actually studied?
Symptoms after stopping 8 weeks of esomeprazole in healthy people.
- B. What did the authors find?
44% vs 15% reported ≥1 relevant symptom in weeks 9–12.
- C. What conclusions do the authors themselves draw?
RAHS has clinical implications.
- D. What does the archive derive from it?
Derives dependency/addiction and 'cannot stop'.
- E. Is this derivation scientifically justified?
Partly: the rebound finding is correctly reported; 'dependency' and 'cannot stop' go beyond a 4-week observation of mostly mild symptoms.
- Adequacy of the interpretation (by the archive)
- partly correct but over-interpreted